An investigation of the molecular mechanisms of IMiDs induced IRF4 and MYC downregulation in multiple myeloma

Research Project

Project/Area Number	15K18418
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Tumor biology
Research Institution	Tokyo Medical University
Principal Investigator	Yamamoto Junichi 東京医科大学, 医学部, 助教 (40748472)
Project Period (FY)	2015-04-01 – 2017-03-31
Project Status	Completed (Fiscal Year 2016)
Budget Amount *help	¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000) Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000) Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords	多発性骨髄腫 / IMiDs / IRF4 / MYC / 転写因子 / がん / 磁性ナノ粒子
Outline of Final Research Achievements	IRF4 and MYC are known as essential genes for survival of multiple myeloma cells. Immunomodulatory drugs (IMiDs) promote the downregulation of IRF4 and MYC expression in multiple myeloma cells. However, the underlying mechanisms are not entirely clear. The purpose of this study was to elucidate the molecular mechanisms of IMiDs induced IRF4 and MYC downregulation. In this study, I attempted to identify protein factors that regulate transcription of IRF4 and MYC. Our results suggest that five genes identified in this study are involved in the expression of IRF4 and MYC and/or IMiDs induced growth inhibition in multiple myeloma cells.

Report

(3 results)